283 related articles for article (PubMed ID: 17198225)
1. Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications.
Essig M; Weber MA; von Tengg-Kobligk H; Knopp MV; Yuh WT; Giesel FL
Top Magn Reson Imaging; 2006 Apr; 17(2):89-106. PubMed ID: 17198225
[TBL] [Abstract][Full Text] [Related]
2. MR imaging of CNS tumors: are all contrast agents created the same?
Essig M
Neuroradiology; 2006 Apr; 48 Suppl 1():3-8. PubMed ID: 16699847
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-perfusion in intra-axial brain tumors with high relaxivity contrast agents.
Cotton F
Neuroradiology; 2006 Apr; 48 Suppl 1():34-40. PubMed ID: 16699850
[TBL] [Abstract][Full Text] [Related]
5. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
6. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.
Choyke PL; Dwyer AJ; Knopp MV
J Magn Reson Imaging; 2003 May; 17(5):509-20. PubMed ID: 12720260
[TBL] [Abstract][Full Text] [Related]
7. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla.
Giesel FL; Mehndiratta A; Risse F; Rius M; Zechmann CM; von Tengg-Kobligk H; Gerigk L; Kauczor HU; Politi M; Essig M; Griffiths PD; Wilkinson ID
Acta Radiol; 2009 Jun; 50(5):521-30. PubMed ID: 19337867
[TBL] [Abstract][Full Text] [Related]
8. Role of MRI in paediatric neurooncology.
Rao P
Eur J Radiol; 2008 Nov; 68(2):259-70. PubMed ID: 18775616
[TBL] [Abstract][Full Text] [Related]
9. Current uses of gadolinium chelates for clinical magnetic resonance imaging examination of the liver.
Low RN
Top Magn Reson Imaging; 1998 Jun; 9(3):141-66. PubMed ID: 9621404
[TBL] [Abstract][Full Text] [Related]
10. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
Fayed N; Dávila J; Medrano J; Olmos S
Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
[TBL] [Abstract][Full Text] [Related]
11. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
12. Use of magnetic resonance imaging in central nervous system tumors.
Jose B; Lindberg R; Spanos W; Paris K
J Ky Med Assoc; 1995 Mar; 93(3):88-92. PubMed ID: 7730730
[TBL] [Abstract][Full Text] [Related]
13. Neuro MR: protocols.
Mikulis DJ; Roberts TP
J Magn Reson Imaging; 2007 Oct; 26(4):838-47. PubMed ID: 17896388
[TBL] [Abstract][Full Text] [Related]
14. Contrast agents: magnetic resonance.
Burtea C; Laurent S; Vander Elst L; Muller RN
Handb Exp Pharmacol; 2008; (185 Pt 1):135-65. PubMed ID: 18626802
[TBL] [Abstract][Full Text] [Related]
15. Transient widespread blood-brain barrier alterations after cerebral photothrombosis as revealed by gadofluorine M-enhanced magnetic resonance imaging.
Stoll G; Kleinschnitz C; Meuth SG; Braeuninger S; Ip CW; Wessig C; Nölte I; Bendszus M
J Cereb Blood Flow Metab; 2009 Feb; 29(2):331-41. PubMed ID: 18957988
[TBL] [Abstract][Full Text] [Related]
16. Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors.
Yuh WT; Fisher DJ; Mayr-Yuh NA; Tali ET; Nguyen HD; Gao F; Ehrhardt JC
Invest Radiol; 1992 Aug; 27 Suppl 1():S39-44. PubMed ID: 1506152
[No Abstract] [Full Text] [Related]
17. 3.0-T functional brain imaging: a 5-year experience.
Scarabino T; Giannatempo GM; Popolizio T; Tosetti M; d'Alesio V; Esposito F; Di Salle F; Di Costanzo A; Bertolino A; Maggialetti A; Salvolini U
Radiol Med; 2007 Feb; 112(1):97-112. PubMed ID: 17310287
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of endothelial permeability in brain tumors by dynamic magnetic resonance tomography with magnevist contrast imaging on low-field MR-tomograph].
Usov VIu; Velichko OB; Borodin OIu; Garganeev AB; Shikunov AA; Boklag ON
Vestn Rentgenol Radiol; 2001; (3):22-9. PubMed ID: 12717930
[TBL] [Abstract][Full Text] [Related]
19. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) alpha-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent.
Lahrech H; Perles-Barbacaru AT; Aous S; Le Bas JF; Debouzy JC; Gadelle A; Fries PH
J Cereb Blood Flow Metab; 2008 May; 28(5):1017-29. PubMed ID: 18183033
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging in oncology: an overview.
Wallis F; Gilbert FJ
J R Coll Surg Edinb; 1999 Apr; 44(2):117-25. PubMed ID: 10230207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
